COMPANY:

Epic Sciences

"Epic Sciences, Inc...has completed a $43 million first close of its Series F financing. The company will use the capital from this additional round of private investment to continue to advance its multi-omic platform and expand operations in areas such as single-cell sequencing and data analytics infrastructure."

"Epic Sciences, Inc. has added DefineMBC™, a novel comprehensive blood-based test for characterizing metastatic breast cancer, to its CLIA laboratory menu...DefineMBC™ includes both cell-based and cell-free analysis from a single blood draw to provide comprehensive profiling of metastatic breast cancer when a tissue biopsy result is not available."

"Epic Sciences, Inc. today announced it has partnered with Fulgent Genetics...to deliver DefineMBC comprehensive profiling results for metastatic breast cancer (MBC) patients. The partnership links Fulgent’s leading CAP/CLIA certified Next Generation Sequencing services with Epic’s best-in-class cell analysis platform as part of Epic’s novel DefineMBC liquid biopsy test."

"Biosplice Therapeutics is partnering with Epic Sciences to incorporate multiomic profiling into Biosplice's clinical oncology programs, the companies said on Thursday...As part of the collaboration, Biosplice plans to use Epic's liquid biopsy platform to characterize drug activity and patient response for its Cirtuvivint (SM08502) investigative drug in two clinical trials."

"Epic Sciences, Inc. announces DefineMBC, a novel metastatic breast cancer (MBC) test that includes both cell-based and cell-free analysis from a single blood draw. DefineMBC provides comprehensive MBC profiling when a tissue biopsy result is not available...DefineMBC combines several multi-analyte assay methods to perform comprehensive cancer profiling and has demonstrated impressive sensitivity, specificity, accuracy, and precision."

"Epic Sciences, Inc. (Epic)'s comprehensive liquid-biopsy platform continues to deliver compelling cancer profiling information as data presented during the San Antonio Breast Cancer Symposium 2021 demonstrate...Poster P2-02-03 Circulating tumor cells (CTCs), CTC heterogeneity and distinct morphological CTC phenotypes predict worse survival in metastatic breast cancer (MBC)"

P1/2, N=37; PRINCE (NCT03658447); "Data from abstract 577O – 'PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC),' being presented by Shahneen K. Sandhu, MD, principal investigator of PRINCE and Associate Professor at the Peter MacCallum Cancer Centre, Victoria, Australia, shows that the majority of patients' circulating tumor cells (CTCs) expressing the target Prostate-Specific Membrane Antigen (PSMA) at baseline were cleared at 12 weeks ,when measured using the Epic PSMA CTC Assay - prior to other response biomarkers in the study."

"Epic Sciences, Inc. and Predicine, Inc. today announced they have entered into a global strategic partnership to offer biopharmaceutical companies access to both Predicine’s ctDNA-based testing and Epic’s CTC-based testing. Predicine’s lead offering is PredicineATLASÔ, the broadest CLIA-certified ctDNA-based assay that analyzes 600 cancer-related genes, using next generation sequencing. Epic’s CTC-based platform offers testing of AR-V7, AR-N term, PSMA, ER, PR and other phenotypic tests. The combination of both approaches allows pharmaceutical partners engaged in clinical trials to measure both genotypic and phenotypic markers from a single blood draw."

"Epic Sciences, Inc. today announced it has entered into a global collaboration with Q2 Solutions…to offer Illumina®’s TruSight Oncology 500 liquid biopsy test to Epic’s global biopharmaceutical customers. The addition of TruSight Oncology 500 to Epic’s portfolio of testing capabilities, brings ctDNA analysis to Epic’s CTC-based platform that enumerates and characterizes circulating tumor cells (CTCs)."